The purpose of this review is to summarize the background and latest evidence for the use of palbociclib, an oral, first-inclass, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice. The available clinical data from both controlled clinical trials and real-life experiences concerning palbociclibbased combinations in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic disease, including patient-reported outcomes and subgroup analyses, have been reviewed and discussed. Palbociclib significantly improved progression-free survival and clinical benefit rates when added to letrozole in postmenopausal women as initial endocrine-based therapy, and it prolonged progression-free survival and overall survival when added to fulvestrant in women who progressed on previous endocrine therapy in randomized clinical trials.
Introduction
Breast cancer (BC) is the second most common cancer overall and the most common cancer in women. Although treatable, metastatic breast cancer (MBC) remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year OS of only 25%. 1 Approximately 70% of BC cases are hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-). Sequential endocrine therapy (ET) is considered the mainstay treatment for premenopausal and postmenopausal women with HR+/ HER2-MBC without extensive visceral involvement, according to all international guidelines. [2] [3] [4] However, the effectiveness of ET is limited by pre-existing endocrine resistance and by resistance acquired during treatment. 5 From a clinical point of view, primary endocrine resistance is defined as a relapse while on the first 2 years of adjuvant ET or disease progression (PD) within the first 6 months of first line ET for MBC. Secondary resistance occurs when a relapse happens after 2 years of adjuvant ET or a PD is evident after 6 months of ET for MBC. 2 These concepts have prompted the development of additional strategies and new classes of agents targeting other patterns of growth, to reverse or postpone ET resistance. Two different strategies are being pursued to improve the efficacy of ET, namely intensification of endocrine manipulations and cotargeting of ER with other molecular components of oncogenic signaling pathways mediating endocrine resistance.
Palbociclib, ribociclib, 6 and abemaciclib 7 have been approved in recent years for the treatment of endocrine-resistant MBC in combination with ET considering their efficacy in prolonging progression-free survival (PFS), increasing clinical benefit rate (CBR) and response rate (RR) in different clinical context and treatment lines.
These agents are orally available, highly selective inhibitors of CDK4 and CDK6, serine-threonine kinases that regulate the ISSN: 1740-4398 REVIEW -Palbociclib in metastatic breast cancer drugsincontext.com cell cycle progression. In fact, when they are activated by the expression of D-type cyclins, they initiate the phosphorylation of retinoblastoma tumor suppressor protein (pRb) with subsequent release of transcription factors from the E2F family. These factors coordinate a gene expression program that is required for determining cell cycle progression, DNA replication, and mitosis. 8 CDK 4/6 inhibitors hamper the phosphorylation of CDK 4/6, leading to hypophosphorylation of pRb and hindering the activation of the transcription factors necessary for S-phase entry. They also determine an arrest of the progression of the cell cycle at the G1 phase, preventing DNA synthesis required for cellular replication. 9, 10 The mechanisms of resistance to these molecules can derive from p16 hyperexpression (mediating intrinsic resistance), activation of alternative proliferative pathways such as mTOR and PI3K (acquired resistance), or deregulation of cyclin expression. 11 This article aims to review the available clinical data from both controlled clinical trials and real-life experience with the use of palbociclib in MBC, because this drug was the first approved in Europe and many data regarding daily practice use are available in the literature. It is also the only CDK4/6 inhibitor for which recent data demonstrated an improvement on OS. [12] [13] [14] 
Methods
In this narrative review, we describe and discuss the evidence from the phase III trials regarding palbociclib use in MBC, providing critical analysis of the specific settings of clinical interest. We also analyze the real-life studies available in the literature, focusing on data regarding the same populations addressed in the perspective trials. Our analysis also concentrates on the toxicity profile of the drug in unselected patients.
Pivotal clinical trials of palbociclib
In 2015, the randomized phase II PALOMA-1 trial defined for the first time the efficacy and activity of palbociclib. 12 The study also evaluated patient-reported outcomes (PROs) using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. These results, published in a different paper, did not show clinically significant differences from baseline in the questionnaire scores, but significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; p=0.0183). In both arms, patients who obtained a CBR to palbociclib had significantly reduced deterioration of FACT-Breast Total score versus patients with PD. No significant differences in FACT-Breast and EQ-5D index scores were observed in patients who developed neutropenia (Table 1) . 16 In the same year, the results of PALOMA-3, a phase III trial, were published. 13 The study randomized 521 women with HR+/HER2-MBC progressing to ET to receive fulvestrant plus palbociclib versus fulvestrant plus placebo. In the overall population, about 80% of patients were endocrinesensitive to prior ET; 80% were postmenopausal and had a DFI>24 months; 25% had not received previous treatment for metastatic disease. The results from this analysis showed that patients receiving palbociclib had a significant improvement of pain and time to deterioration questionnaire scores (Table 1) . 17 In 2018, the results of the phase II of the TREND trial were released. In this study, 115 women with HR+/HER-MBC progressing on prior ET were randomized to receive palbociclib alone or in combination with the ongoing ET. The last ET was an aromatase inhibitor (AI) in 60 and 50% of patients in the combination arm and monotherapy arm, respectively, and fulvestrant in 38 and 50%, respectively. About 75% of patients had visceral metastasis, and 7% of patients had a bone-only disease. A randomization 1:1 was performed with the following prespecified stratification factors: number of previous ET lines (1 versus 2), duration of prior-line ET (≤6 versus >6 months), metastatic disease site (visceral versus nonvisceral), and treating center. The trial results were negative for its primary endpoint of CBR (54 versus 60%, p=0.52, for the combination arm versus the palbociclib alone arm, respectively). As for the secondary endpoints, median PFS was not statistically significant for the palbociclib arm (10.8 versus 6.5 months, p=0.12); however, a greater duration of CBR was obtained in the palbociclib arm (11.5 versus 6 months, p=0.0021). The most common grade 3-4 AEs in the combination arm were neutropenia (72%), leukopenia (38%), and mucositis (5%); those in the palbociclib monotherapy arm were neutropenia (70%) and leukopenia (33%) ( Table 1) . 18 
Subgroup analysis of pivotal clinical trials
Visceral and liver metastasis Visceral metastases were highly prevalent in patients enrolled in the PALOMA studies (PALOMA-1: 48%, PALOMA-2: 48.6%; PALOMA-3: 58.3%) and in the TREND trial (76%). The most common site for visceral metastases was the liver (PALOMA-1: not specified; PALOMA-2: 37%; PALOMA-3: 67%; TREND: not specified), followed by the lung (PALOMA-3: 28%; PALOMA-1, PALOMA-2, and TREND: not specified). 19 Regarding the primary endpoint of the PALOMA trials, patients with visceral metastasis had a greater PFS with palbociclib than in the control arms (PALOMA 
Menopausal status
In all trials, pre-and perimenopausal patients were made functionally menopausal by using goserelin for ovarian suppression before randomization. This hampers the drawing of conclusions regarding the primary and secondary endpoints. Besides, the PALOMA-3 trial is the only trial that clearly reported separate results for pre-/perimenopausal and postmenopausal patients. However, no differences were seen in PFS in the pre-or peri-menopausal patients (9.5 versus 5.6 months in the experimental and control arms, respectively, p=not reported) and in the postmenopausal group (9.9 versus 3.9 months, in the experimental and control arms, p=not reported).
Elderly
Elderly patients, defined as patients aging ≥65 years, represented about 46% of patients in the PALOMA-1 trial, 39% in PALOMA-2, and 25% in PALOMA-3. In the TREND trial, these data were not reported. A recent pooled analysis by Rugo and colleagues on elderly patients showed that, also in this subgroup, PFS was significantly improved in patients receiving palbociclib (in PALOMA In both PALOMA-2 and PALOMA-3 trials, elderly patients had a similar baseline health-related QoL scores (HRQoL) to younger ones. Palbociclib in addition to either fulvestrant or letrozole did not result in significant deterioration in well-being scale or total FACT-B scores. In the PALOMA-3 trial, in the 65-74 year-old group, the combination arm resulted in a statistically significant delay in deterioration in pain scores. 21 Endocrine resistance
In the PALOMA-3 trial, sensitivity to previous ET was a prespecified stratifications factor. In the TREND trial, number of previous ET lines (1 versus 2) and duration of prior-line ET (≤6 versus >6 months) were prespecified stratifications factor.
In PALOMA-3, endocrine-sensitive patients were about 78% of the total population. In the TREND trial, about 70% of patients had received one ET line, and 30% had received more than two ET lines; 26% of patients had a duration of prior ET ≤6 months and 74% a duration >6 months. Oligometastatic disease versus widely metastatic disease
Patients with limited number and sites of metastasis account for 30% of PALOMA-2 and PALOMA-3. According to primary endpoints, in the PALOMA-2 trial, patients with oligometastatic disease had a similar PFS to plurimetastatic ones (HR 0.51 versus 0.61, p=not reported); the same results were reported in PALOMA-3 patients (p interaction=0.43). However, in the update analysis of PALOMA-3, a greater benefit in PFS was observed for patients with only one or two disease sites who were treated with palbociclib (13.4 versus 5.6 months, p=not reported). 20 No subgroup analysis regarding safety and QoL evaluation was performed.
Real-life studies
Among 21 real-life experiences with palbociclib-based combinations that are available in the literature (Table 2) , only 5 comprised a prospective design. Enrolled population, therapeutic line, and companion drug are highly heterogeneous. More than 6000 patients have been included in these studies.
Palbociclib in combination with letrozole or fulvestrant
Two trials 22, 23 evaluated the combination of palbociclib with letrozole and one with fulvestrant. 24 In the remaining studies, palbociclib was administered in combination with different ETs that could be an AI, fulvestrant, tamoxifene, or others (megestrol).
The trial by Masuda and colleagues, which enrolled 42 Japanese patients, had 1-year PFS probability as the primary endpoint; among secondary endpoints were efficacy, activity, safety, and tolerability. In a subset of patients, an analysis of the pharmacokinetic (PK) profile and of the possible biomarkers of tumor sensitivity and/or resistance in tumor tissue samples (such as the Ki-67 index) was performed. Regarding the primary endpoint, the 1-year PFS probability was 75%, similar to the results of PALOMA-1 and PALOMA-2 trials; among secondary endpoints, mPFS and mOS were not reached, 40.5% had an ORR, 85.7% a disease control, and the 1-year survival probability was 92.2%. Health-related QoL data were not reported. From the subgroup analysis, great insight on the effect of patients' baseline characteristics can be noticed because patients with higher PFS had nonvisceral metastasis and de novo metastatic disease. In fact, patients with nonvisceral versus visceral metastasis evidenced a higher 1-year PFS (95.2 versus 51.8%, p=not reported, respectively) and a greater mPFS (not reached versus 16.7 months, p=not reported). A different probability of 1-year PFS was evident according to patient's DFI from the primary diagnosis: 60% if DFI ≤12 months, 79.3% if DFI >12 months, and 78.9% if de novo metastatic disease. Moreover, patients with a Ki-67 ≤20% had a higher PFS (not reached versus 16.7 months). In total, 59.5% of patients required at least a dose reduction; in these patients, mPSF was not reached versus 16.7 months in patients who did not have a dose reduction. Most of the toxicities were manageable by dose modifications and/ or therapy support. Only three serious AEs were described (subarachnoid hemorrhage, febrile neutropenia, and cerebral hemorrhage). The PK analysis provided data similar to the nonJapanese population of PALOMA-1. 22 In the trial by Stearns, 334 patients with MBC in an expandedaccess study program (EAP) were analyzed. The primary endpoint was safety; secondary endpoints were efficacy and activity in the Canadian cohort of patients. For the first time, PROs and pain were evaluated using the EuroQol-5D (EQ-5D) questionnaire and the visual analogue scale (VAS). Toxicity was consistent with PALOMA-1 and PALOMA-2 trials. The general health status, QoL, and pain control were maintained during the treatment with minimal changes from baseline. 23 A third trial by Du Rusquec and colleagues included 60 patients treated with fulvestrant plus palbociclib. The remaining studies have smaller sample sizes. Ban and colleagues enrolled 24 patients with a primary endpoint of activity and secondary endpoint of efficacy and safety. A SD was obtained in 58.3% of patients; No objective response was observed. Median PFS was 4.8 months and mOS was 11 months were favorable with the mPFS and mOS expected with singleagent CT in a similar cohort of patients. The toxicity profile was favorable, with hematological toxicities being the most commonly reported. The only difference from clinical trial was the incidence of grade 3 thrombocytopenia due to the great exposure to previous CT in the population. 27 The study by Dhakal and colleagues enrolled 23 everolimus pretreated patients to receive palbociclib in combination with fulvestrant or AI according to physician's choice. In this trial, a very reduced mPFS and CBR were observed in contrast with the PALOMA-3 trial (2.9 months and 17.4%, respectively), confirming a greater benefit of palbociclib in earlier lines of treatments. However, in the overall population, mOS was 19.8 months. No safety data were reported. 28 A study performed by Palumbo and colleagues enrolled 150 postmenopausal patients divided into two cohorts: the cohort A (65 patients) received palbociclib plus letrozole, whereas the cohort B (85 patients) received palbociclib plus fulvestrant. The primary endpoint was CBR, secondary endpoints were PFS and safety. In cohort A, a CBR of 52% and a mPFS of 6.3 months were observed; whereas, in cohort B, the CBR was 60% and PFS 5.5 months. However, PFS was better in patients treated as ≤3rd versus >3rd line (p=0.003 in cohort A and p=0.002 in cohort B) suggesting a better outcome for earlier use of palbociclib. Safety profile was similar to the other real-life experiences with a prevalence of neutropenia (grade 1-2 in 67% and grade 3-4 in 35% of patients in both cohorts). 29 A smaller trial by Maurer and colleagues reported the activity and safety of palbociclib in combination with any ET administered in 34 heavily pretreated patients within a compassionate use program in Belgium. The objectives of the study were activity, in terms of ORR by RECIST and PERCIST criteria, and disease control rate (DCR) at 12 and 24 weeks, efficacy in terms of OS and PFS, and safety. Most patients had already been treated with ET (76.5%) or with mTOR inhibitors (82.4%). In the group of patients evaluable with RECIST (N=14), PR was 7.1%, SD was 64.3%, and PD was 28.6%. In the group evaluable by PERCIST (N=19), CR was 5.3%, PR 10.5%, SD 15.8%, and PD 68.4%. Irrespective of the type of response assessment, DCR was 52.9% at week 12 and 24.4% at week 24. Median PFS was 3.1 months in the overall cohort; no differences in PFS was observed between mTOR inhibitor-pretreated and naïve patients. Median OS was not reached. The most common AEs were neutropenia (76.5%); febrile neutropenia occurred only in one patient. Dose reductions and/or interruptions occurred in 29.4% of patients. 30 heavily pretreated with a median of 5 (range 1-14) previous treatment lines. All of them had already received everolimus, and 46.8% fulvestrant. As expected in advanced treatment lines, the median PFS was inferior to PALOMA-3 trial results (5.8 versus 9.5 months, respectively). However, in fulvestrant pretreated patients, this reduction was less pronounced (6.4 months). These data are in contrast with a subgroup analysis of the PALOMA-3 trial in which patients who received ≥3 lines of treatment did not derive any benefit from the addition of palbociclib to ET. Conversely, it is consistent with the TREND trial results, assuming that palbociclib could reverse the acquired resistance to ET. The median PFS was not influenced by the previous treatment with everolimus, and it was similar for patients with bone-only and visceral disease. Interestingly, it was possible to evaluate PFS in 40 patients receiving a subsequent treatment line (38 CT, 2 ET); the observed PFS of 3.3 months was similar to that described in the PALOMA-3 trial. 24 Heavily pretreated patients Another trial by Gong and colleagues evaluated the toxicities observed with palbociclib in combination with ET and the resulting dose modifications and prescriber's preferences in modifying the drug dose. A total of 100 patients were included: 38% of them required dose modifications, most of which occurred during the first two cycles of therapy (81.6%). A smaller proportion of patients (10.6%) required dose modifications during cycles 3-4, and three patients (7.8%) needed changes in palbociclib dose beyond cycle 5. The most common reason for modifications in dose and schedule was toxicity, being grade 3-4 neutropenia the most common (54.8%) followed by grade 3-4 thrombocytopenia (11.8%), grade 2-3 mucositis (9.5%), and grade 2-3 fatigue (4.8%). Consistently with Rugo and colleagues, 21 age >65 did not affect treatment compliance. 34 In a trial by Watson and colleagues of palbociclib and ET, 28 patients on 64 had treatment deferrals due to neutropenia, with a median time to first deferral of 4 weeks. Fifteen patients required dose adjustments; however, there was no association with an increased risk of progressive disease. For the first time, a high incidence of thromboembolic events was reported (11 versus 2% of PALOMA-3 trial). However, it is difficult to establish whether these events were drug related or disease related. 35 Additional studies 36, 37 are summarized in Table 2 and are consistent with the data previously reported in activity and safety. Interestingly, Pizzuti and colleagues reported a reduced ORR in patients with prior exposure to everolimus/ exemestane (16.7 versus 34.5%, respectively, p=0.002) and a higher ORR and CBR in patients without visceral metastasis (p=0.0004 and 0.04, no data available). On the other hand, no statistically significant difference in ORR was observed according to previous fulvestrant exposure (31.7 versus 29.6%, p=0.72) and menopausal status. The study also supports the use of palbociclib in an elderly population (≥75 years) with no differences in the toxicity profile depending on treatment line and patients' age. 37 
Quality of life
In the study by Darden and colleagues, the treatment satisfaction of patients receiving palbociclib was evaluated using the Cancer Therapy Satisfaction Questionnaire (CTSQ), a validated instrument that measures patients' expectations and satisfactions with treatments. It was developed for the use in patients with any type of cancer regardless of the stage and type of treatment used. 43 The trial was a web-based survey including 604 patients from six countries (the United States, Canada, Germany, Netherlands, Argentina, and Denmark). The questionnaire was translated into the appropriate native language for each country. They found that more than 96% of patients enrolled met or exceeded their expectations regarding the treatment. These results were not influenced by the type of the combination treatment (AI or fulvestrant) or by visceral involvement. 38 
Conclusions
The introduction of CDK 4/6 inhibitors in combination with ET is considered the most important advance in recent years for the management of luminal MBC. 2 Palbociclib is the first member of the CDK4/6 inhibitors entering the clinical arena. With more than a 10-month improvement in mPFS when added to letrozole or fuvestrant, it represents one of the ISSN: 1740-4398 REVIEW -Palbociclib in metastatic breast cancer drugsincontext.com best steps forward in the treatment of luminal breast cancer. The significant improvement in mPFS demonstrated across the PALOMA trials occurred in all subgroups, regardless of stratification factors or other baseline characteristics. In addition, a recent update suggests that the use of palbociclib plus fulvestrant provides a substantial survival benefit, especially in patients with disease recurrence during adjuvant ET for at least 2 years, or in patients who received ET for metastatic disease with a high CBR. 14 However, despite improved clinical outcomes, PD eventually occurs, and women with HR+ MBC require multiple lines of therapy. Identifying response predictors will be essential for rational use of the drug to avoid unnecessary toxicity and costs.
Beyond results from randomized clinical trials, on which guidelines are based, clinicians in daily practice encounter a wide array of clinical presentations. With this in mind, the increasing body of data from real-world studies provide important information regarding the performance of the drug. Collectively, the real-life studies confirm the results of the randomized trials, as palbociclib plus ET appear to be effective and safe also in unselected patients. The primary objectives of these trials were activity and efficacy of the palbociclib combinations. Secondary endpoints were toxicity and, in one trial, 38 patients' treatment satisfaction according to CTSQ. As expected, activity and efficacy were related to the line of treatment in which palbociclib was used; trials enrolling heavily pretreated patients reported a low activity and efficacy of the combination. As in the phase II-III trials, no clinical subgroup depending on age, menopausal status, endocrine resistance, pretreatment, disease site, and its extension has been found to be related with a specific outcome.
Further, a systematic approach will likely be necessary to better identify the range of biomarkers associated with response or resistance, as well as the optimal sequence to use for the best benefit in each patient. 
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